Abeona Therapeutics Inc.

Stage 4 · Declining · week 1

As of Oct 22, 2026, Abeona Therapeutics is in Stage 4, the downtrend phase, now in its first week (since Oct 21, 2026). It closed at $4.47, 40.1% below its 52-week high and below its 200-day average, which is falling.

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. More about the company

$4.47

-0.89% today

$256M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ABEO early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 31w

S2 15w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 1w → S3 6w → S2 31w → S3 5w → S4 6w → S1 11w → S2 10w → S3 12w → S4 8w → S1 5w → S2 15w → S3 5w → S4 11w → S1 7w → S4 6w → S1 5w → S2 15w → S3 5w → S4 1w current

Total tracked: 165 weeks across 19 stage runs.

ABEO among Biotechnology240th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…240	ABEOAbeona Therapeutics Inc.	Stage 4 · wk 1	40	−19.2%

vs 52W High

-40.1%

$4.17 lo$7.46 hi

40.1% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 1

1w13w26w

Week 1, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-18.9%

200 DMA: $5.51 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.49x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-19.2%

-26.1%

-19.0%

YTD

-15.8%

-18.3%

Scan Membership

Breakout Watch

Latest: 2025-06-18

6 appearances in last 60 days. First seen: 2020-06-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 1 · Vol 0.49x

2026-10-21S43→4

Wk 1 · Vol 0.67x

2026-10-20S3

Wk 5 · Vol 0.94x

2026-10-19S3

Wk 5 · Vol 0.66x

2026-10-16S3

Wk 5 · Vol 0.55x

2026-10-15S3

Wk 4 · Vol 0.93x

2026-10-14S3

Wk 4 · Vol 1.20x

2026-10-13S3

Wk 4 · Vol 1.36x

2026-10-12S3

Wk 4 · Vol 0.52x

2026-10-09S3

Wk 4 · Vol 0.89x

2026-10-08S3

Wk 3 · Vol 1.13x

2026-10-07S3

Wk 3 · Vol 0.51x

Moving averages & range

50 DMA

$5.44

200 DMA

$5.51

52W High

$7.46

52W Low

$4.17

5D Low

$4.41

Resistance levels (recent highs)

20d High

$5.40

60d High

$7.46

120d High

$7.46

250d High

$7.46

Next resistance

+20.8%

to 20d High

ROE

-43.1%

Profit margin -246.4%

Dividend Yield

0.00%

P/B 2.0

Abeona Therapeutics: quick answers

What stage is Abeona Therapeutics in?

As of Oct 22, 2026, Abeona Therapeutics (ABEO) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 21, 2026 and is in its first week there. What the four stages mean

Is Abeona Therapeutics in an uptrend?

No. Abeona Therapeutics is in a Stage 4 downtrend. It trades 18.9% below its 200-day average, which is falling.

How far is Abeona Therapeutics from its 52-week high?

Abeona Therapeutics closed at $4.47 on Oct 22, 2026, 40.1% below its 52-week high of $7.46. Its 52-week low is $4.17.

How has Abeona Therapeutics performed over the past year?

As of Oct 22, 2026, Abeona Therapeutics is down 18.3% over the past year and down 15.8% so far in 2026.

Which sector and industry is Abeona Therapeutics in?

Abeona Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.